During a drug shortage, patients often hear the word “unavailable” before they hear what happens next. A pharmacy can reduce fear and repeat calls by communicating what is known, what is not known, who is working on the issue, and when the patient should expect an update—without promising a supply date, a therapeutic alternative, coverage, or a result that the pharmacy cannot control.
Answer first: use a shortage communication process that verifies the product and patient need, checks legitimate supply and payer information, tells the patient the immediate next step in plain language, coordinates with the prescriber when a change may be needed, documents the contact, and sets a realistic update point. FDA’s shortage resources provide current product, manufacturer, reason, and estimated-duration information, but individual availability and treatment options remain patient- and location-specific.
This is general operational education, not individualized medical, prescribing, compounding, or legal advice. Patients should speak with their pharmacist and prescriber about an individual medication problem. Pharmacies should follow applicable laws, payer rules, and professional standards.
Contents
- Separate confirmed facts from assumptions
- A patient-safe shortage workflow
- Messages that help without overpromising
- Coordinate changes with the prescriber
- Avoid unsafe supply shortcuts
- Communication checklist
- FAQ
Key takeaways
- Check a reliable source and the pharmacy’s actual supply before stating that a product is in shortage or available.
- Tell patients what the pharmacy will do next and when they can expect an update; do not invent an availability date.
- Medication alternatives, dose changes, or therapeutic substitutions require patient-specific clinical review and may require prescriber action.
- Do not use a shortage as a reason to buy from an unknown source or promote compounded products without evaluating applicable requirements.
- Use consistent documentation so staff can continue the conversation without asking the patient to start over.
Start with confirmed facts, not shortage rumors
A patient may report that a medication is “gone everywhere,” while the pharmacy may have a local wholesaler allocation, a delayed order, a particular package-size issue, an insurance obstacle, or a prescription timing problem. Start by identifying the exact product, strength, dosage form, quantity, expected refill date, remaining supply if known, and urgency. Then separate three questions: is the product listed by FDA as in shortage; what can this pharmacy obtain through legitimate channels; and what is appropriate for this patient?
FDA’s Drug Shortage Staff maintains a searchable public database with information about products in shortage, including availability, supply, estimated duration, manufacturer information, and reasons. FDA says much of the information is supplied by manufacturers and updates are posted as they are received. That makes the database a strong public reference, not a promise that a particular pharmacy will have stock at a particular time. Explain this distinction plainly to patients and staff.
Use one internal source of truth for the day: a shortage queue or note with product details, verified supplier status, patient contacts, prescriber status, next review date, and owner. Do not rely on staff memory, informal group chats, or a patient’s social-media post. The aim is continuity: the next team member should understand what has been checked and what remains without repeating the same uncertain claims.
A patient-safe shortage workflow
1. Triage urgency and remaining supply
Ask how much medication remains and whether the patient is experiencing an urgent problem. Follow the pharmacy’s clinical escalation policy for urgent concerns. Do not tell a patient to stop, stretch, split, substitute, or change a medication without appropriate clinical direction. The operational goal is to prioritize communication and routing, not to make an individualized treatment decision from an inventory screen.
2. Verify the product and legitimate supply
Confirm the exact prescription and inspect the pharmacy’s normal, authorized supply channels. Review the FDA shortage database when relevant. Record what was checked, when, and the result. If a wholesaler offers an unfamiliar product, quantity, or price, escalate to the purchasing and compliance process rather than treating scarcity as permission to bypass vendor verification. FDA’s shortage FAQ warns that unknown distributors may advertise shortage drugs to pharmacies at unusually high prices.
3. Give the patient a clear next step
A useful first message is specific about process: “We are checking our authorized suppliers and will update you by tomorrow afternoon,” or “We need the prescriber to review options; we have sent the request and will contact you when we hear back.” Avoid “it should be here soon,” “everyone is out,” “your insurance will cover it,” or “we can switch you” unless the relevant fact or authority is confirmed.
| Situation | Helpful message | Avoid |
|---|---|---|
| Product unavailable locally | “We are checking our normal suppliers and will update you by [time].” | “It will be back next week.” |
| Prescriber review needed | “We will contact the prescriber to review appropriate options.” | “You should take this instead.” |
| Insurance question | “We will check the claim requirements for the prescribed option.” | “This alternative is covered.” |
| Patient requests compounding | “A pharmacist can review whether that is appropriate and available.” | “A compounded version is the same.” |
| No confirmed date | “We do not have a confirmed arrival date; here is when we will check again.” | “The shortage is over.” |
Build a small library of transparent messages
Templates should save time without turning a shortage into a scripted dead end. Keep one short first-contact message, one prescriber-update message, one delayed-supply message, and one resolution message. Each template should include the patient’s next step, the team’s owner, and an update time. Remove details that a staff member cannot confirm. Let the pharmacist personalize the message when the patient has a clinical question, a limited supply, a language need, or a documented communication preference.
Be careful with phrases that sound reassuring but obscure uncertainty. “We are working on it” is less helpful than “We checked our regular supplier today; there is no confirmed date. We will recheck tomorrow and call you by 3 PM.” The second statement gives the patient a concrete expectation and gives the pharmacy a follow-up obligation. If the next step changes, update the patient before the promised time where possible.
Coordinate changes with the prescriber
FDA’s shortage FAQ states that whether alternatives are appropriate depends on the individual patient and encourages patients having difficulty obtaining a drug to reach out to their health-care provider. A pharmacy can gather the information a prescriber needs: current prescription, medication history available to the pharmacist, supply status, formulary or claim information when verified, and the patient’s remaining supply. It should not convert an inventory workaround into an individualized treatment recommendation without the appropriate authority and clinical review.
Make prescriber requests easy to act on. State the product and shortage or supply issue, the remaining supply reported by the patient, the decision or authorization needed, and a direct pharmacy contact. Track sent time, response, and final action. If a response is delayed and the patient’s supply is becoming urgent, follow the pharmacy’s escalation process rather than repeatedly sending the same message without a new plan.
Assign ownership across the day
Shortage work can fail at handoff. At opening, a designated team member should review new supply notices, urgent patient cases, expected deliveries, and pending prescriber messages. During the day, staff should record completed checks and any promise made to the patient. At closing, the pharmacist or manager should identify cases that require an after-hours instruction or next-morning follow-up. This does not require a large new system; it requires a visible queue with a patient-safe minimum data set and a clear owner for each next action.
Use a single update cadence when several patients are affected by the same product. For example, the owner can recheck an authorized supplier once each morning and afternoon, then update the documented patients using the same accurate status. That reduces repeated calls to wholesalers and prevents different staff members from giving inconsistent estimates. Individual urgent cases still need clinical escalation rather than a batch message.
Document communication, not just inventory
Record the patient’s preferred contact route, the date and time of each contact, the person reached, what was explained, the next promised update, and whether a prescriber request was sent. Avoid recording speculation as fact. A note such as “supplier has no confirmed date; patient advised pharmacy will recheck Tuesday; prescriber request sent at 2:15 PM” is more useful than “drug unavailable.” It helps the next staff member continue the process and shows that the pharmacy communicated uncertainty honestly.
Review a small sample of shortage cases after resolution. Did the patient get an update when promised? Was the prescriber request complete? Did staff avoid unsafe claims about availability or substitution? Did an unfamiliar supplier offer trigger an escalation? Use the answers to improve the template, queue, training, and purchaser communication. The review is a quality-improvement activity, not a reason to rewrite the historical record.
Prepare patients before a shortage affects them
Routine medication conversations can reduce last-minute pressure. Encourage patients to keep their contact information current, request refills according to the prescription and payer rules, tell the pharmacy about travel or access barriers, and contact the team promptly if a medication looks different or is delayed. FDA encourages patients to speak with their pharmacist and health-care provider when their usual medication is unavailable. The pharmacy can reinforce that message without telling patients to stockpile or change their own regimen.
Avoid unsafe supply shortcuts
Shortages create pressure to purchase products from unfamiliar sources. Keep normal purchasing, DSCSA, licensing, product-tracing, and suspect-product procedures active. FDA’s DSCSA materials state that dispensers should accept prescription drugs with required tracing documentation, retain that documentation, and investigate suspect products. Scarcity does not reduce these responsibilities.
Compounding requires equally careful communication. FDA explains that a compounded drug may be appropriate when a patient’s needs cannot be met by an FDA-approved drug or an approved drug is not commercially available, but also notes that compounded drugs do not undergo FDA review for safety, effectiveness, or quality before marketing. Do not describe a compounded product as automatically equivalent, FDA-approved, or the right choice for every patient. Route the request for pharmacist and prescriber review under applicable law and policy.
Drug-shortage communication checklist
- Confirm the exact product, prescription, patient contact, and remaining supply.
- Check legitimate pharmacy supply and authoritative shortage information when relevant.
- Document what is confirmed, what is unknown, and the next owner.
- Give the patient a specific update time rather than an unsupported supply prediction.
- Route clinical alternatives and changes to the appropriate pharmacist and prescriber workflow.
- Verify payer information before making a coverage statement.
- Use only authorized suppliers and follow DSCSA and purchasing controls.
- Document the final outcome and improve recurring communication gaps.
Frequently asked questions
Does an FDA shortage listing mean every pharmacy is out?
No. FDA’s public information describes the product shortage, but individual pharmacy supply can vary. Check the pharmacy’s actual authorized supply and communicate what is known.
Can a pharmacy promise when a shortage will end?
No. Share a confirmed source only with appropriate context and set an internal recheck time. Do not represent an estimated date as a guarantee.
Can a pharmacist automatically substitute another medication?
Medication changes are patient- and jurisdiction-specific. Follow applicable law, pharmacist authority, prescriber direction, and clinical review.
Are compounded drugs the same as FDA-approved drugs?
No. FDA explains that compounded drugs do not undergo FDA review for safety, effectiveness, or quality before marketing. Suitability requires an individual clinical and legal review.
What if a patient cannot wait for the next update?
Use the pharmacy’s clinical escalation process. Confirm remaining supply and route the patient to the pharmacist and prescriber as appropriate. Do not promise an alternative, advise a dose change, or direct the patient to an unverified supplier simply because the situation feels urgent.
Conclusion
A shortage conversation should leave a patient with a next step, not a vague promise. Verify the product and supply, communicate uncertainty honestly, coordinate clinical decisions through the right people, and preserve safe purchasing controls. For related medication-access workflow guidance, see Dispense Times’ diabetes medication-access framework.
References
- U.S. Food and Drug Administration. Frequently Asked Questions about Drug Shortages. Accessed July 19, 2026.
- U.S. Food and Drug Administration. Drug Shortage Staff. Accessed July 19, 2026.
- U.S. Food and Drug Administration. Managing Drug Shortages. Accessed July 19, 2026.
- U.S. Food and Drug Administration. Compounding When Drugs Are on FDA’s Drug Shortages List. Accessed July 19, 2026.
- U.S. Food and Drug Administration. Pharmacists: Utilize DSCSA Requirements to Protect Your Patients. Accessed July 19, 2026.
